Abstract
Importance Screening Lynch syndrome in the general population, including healthy individuals, aims to detect and prevent cancers early. Current clinical recommendations for those with pathogenic variants are based on studies of patients with cancer or strong family history. It is essential to ensure guidelines are based on accurate assumptions regarding the impact of pathogenic variants in Lynch syndrome genes.
Objective To determine the risk of cancer associated with pathogenic variants in MLH1, MSH2, MSH6, or PMS2 in the general population.
Design, Setting, and Participants This retrospective case-control study utilizes Helix Research Network™ data from 144,852 participants across seven US health systems sequenced between 2018 and 2024.
Main outcomes and measures An automated pipeline based on the ACMG-AMP guidelines was developed for variant interpretations. Clinical diagnoses were identified from electronic health records for 11 cancer types associated with Lynch syndrome including colorectal and endometrial cancers.
Results Individuals with pathogenic variants in MLH1, MSH2, and MSH6 were at significantly increased risk for Lynch syndrome-associated cancers with Hazard Ratios (HR) of 16.5 (95% Cl: 8.9-30.8) for MLH1, 17.3 (7.8-38.6) for MSH2 and 4.7 (3.2-6.9) for MSH6. No significant risk was associated with PMS2 pathogenic variants when considering all 11 cancers combined. PMS2 pathogenic variants were only associated with colorectal cancer (HR of 4.3, 1.6-11.4); however, this risk was observed only after the age of 60, 10 years after clinical guidelines recommend starting colonoscopies for the average population. Up to age 60, 0.6% of individuals with PMS2 pathogenic variants were diagnosed with colorectal cancer, similar to 0.4% in the general population but lower than MLH1 (41.0%), MSH2 (17.9%) or MSH6 (4.5%) pathogenic variants.
Conclusion and relevance The findings underscore the benefits of screening the entire population for MLH1, MSH2 and MSH6. They also highlight significantly lower cancer risk for those harboring PMS2 pathogenic variants. This study provides data to support tailored surveillance and prevention strategies by gene and highlights the importance of deriving clinical recommendations from relevant populations.
Competing Interest Statement
K.M.S.B., C.H., J.L., K.L., W.L., E.T.C., and A.B. are employees of Helix Inc. No other disclosures were reported.
Funding Statement
Funding was provided to the Desert Research Institute by the Renown Institute for Health Innovation and the Renown Health Foundation. Funding was provided to DRI by the Nevada Governor Office of Economic Development. Funding was provided to the myGenetics program by HealthPartners. Funding was provided to C.A.A.C. by the European Union's Horizon Europe, under grant agreement No 101136962. Funding was provided to C.A.A.C. by UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee [grant agreements No 10098097, No 10104323]. Funding was provided to C.A.A.C. by Federal Deparment of Economic Affairs, Education and Research EAER, State Secretariat for Education, Research and Innovation SERI.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Helix Research Network protocol has been IRB-approved, enabling secondary research use of data. Approvals for the protocol were granted by the Salus IRB (reliance on Salus for all sites; approval number 21143), the WCG IRB (Western Institutional Review Board, WIRB-Copernicus Group; approval number 20224919), the MUSC Institutional Review Board for Human Research (approval number Pro00129083), and the University of Nevada, Reno Institutional Review Board (approval number 7701703417). All participants provided written informed consent prior to participation. All data used for research had direct identifiers removed to safeguard participant privacy.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos